levodropropizine / Generic mfg. - LARVOL DELTA

Development and validation of HPLC-FLD method for simultaneous determination of ternary therapy used for COVID-19 in plasma samples. (PubMed, Sci Rep) - "A novel green sensitive micellar HPLC method with fluorescence detection is introduced for the analysis of remdesivir, levodropropizine, and moxifloxacin hydrochloride as ternary therapy for COVID-19 in human plasma samples using losartan as internal standard. Eco scale, GAPI and AGREE confirmed the greenness of the method which shows the least impact on the environment along with high score for eco-friendliness. This creates a new approach for routine quality control and pharmacokinetic research of remdesivir, levodropropizine and moxifloxacin hydrochloride."

Journal • Infectious Disease • Novel Coronavirus Disease

Cloperastine in paediatric and adult cough management: a historical narrative review. (PubMed, Drugs Context) - "Moreover, cloperastine exhibits a quarter of the antihistaminic potency of diphenhydramine, does not impair mucociliary clearance and relaxes bronchial smooth muscle...It demonstrated superior or comparable efficacy to codeine, clobutinol, dextromethorphan, levodropropizine, butamirate and dihydrocodeine. In paediatric populations, it improved sleep quality and sputum quality. Cloperastine is a well-tolerated and effective antitussive with a rapid onset, favourable safety profile and low risk of central nervous system side-effects, supporting its role as a valuable therapeutic option for dry cough across all ages."

Journal • Review • Chronic Cough • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases

Pragmatic management of acute cough in children and adolescents: an updated position paper by the Italian Society of Pediatric Allergy and Immunology (SIAIP). (PubMed, Allergol Immunopathol (Madr)) - "This position paper provides an updated, pragmatic framework for the management of acute and post-viral cough in children and adolescents. It promotes rational drug use, integration of non-pharmacological and complementary measures, and awareness of emerging therapeutic targets. A mechanism-driven, individualized, and family-centered approach is advocated to improve clinical outcomes and quality of life for pediatric patients."

Journal • Allergy • Cough • Immunology • Infectious Disease • Inflammation • Mood Disorders • Novel Coronavirus Disease • Pediatrics • Psychiatry • Respiratory Diseases

Innovative Tools and Perspectives in Cough Management: Cancer and Cough. (PubMed, Tuberc Respir Dis (Seoul)) - "If needed, add centrally acting antitussives such as codeine or dextromethorphan, followed by peripherally acting agents (e.g., levodropropizine, benzonatate, or levocloperastine). Emerging therapies like NK1 receptor antagonists show promise for refractory cases. High-quality trials are needed to further validate these approaches and integrate them into standard care to improve the quality of life of patients with lung cancer."

Journal • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS (clinicaltrials.gov) - P4 | N=196 | Completed | Sponsor: Pontificia Universidad Catolica de Chile | Active, not recruiting ➔ Completed

Trial completion • Cough • Infectious Disease • Respiratory Diseases

Comparative Analysis of Classic and Novel Antitussives on Cough Suppression in Guinea Pigs. (PubMed, Pharmaceutics) - " This study evaluated and compared the antitussive efficacy of classic (codeine, cloperastine, dextromethorphan, levodropropizine) and novel (gefapixant) agents using a citric acid-induced cough model in guinea pigs. These findings highlight the potential clinical relevance of both centrally and peripherally acting non-opioid alternatives. Continued investigation of these agents may help address the unmet need for safer and more effective cough treatments."

Journal • Cough • Respiratory Diseases

CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS (clinicaltrials.gov) - P4 | N=196 | Active, not recruiting | Sponsor: Pontificia Universidad Catolica de Chile | Recruiting ➔ Active, not recruiting

Enrollment closed • Cough • Infectious Disease • Respiratory Diseases

Pharmacologic Interventions for Symptomatic Treatment of Cough among Adults with Lung Malignancy: A Systematic Review and Meta-Analysis (APSR 2025) - "Results : Thirteen studies met the inclusion criteria and these examined the use of aprepitant (two), levodropropizine (three), opioid and its derivatives (six), paroxetine (one), and pregabalin (one). Aprepitant showed significant improvement in cough among lung cancer patients. Additional good quality trials are recommended to refine and expand current guideline recommendations."

Retrospective data • Review • Addiction (Opioid and Alcohol) • Cough • Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

PHARMACOLOGIC INTERVENTIONS FOR SYMPTOMATIC TREATMENT OF COUGH AMONG ADULTS WITH LUNG MALIGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS (CHEST 2025) - " Thirteen studies met the inclusion criteria and these examined the use of aprepitant (two studies), levodropropizine (three studies), opioid and its derivatives (six studies), paroxetine (one study), and pregabalin (one study). The most common presenting symptom of lung cancer remains undertreated with limited pharmacologic options available. Aprepitant showed significant improvement in cough among lung cancer patients. There remains a need increase the quality and number of studies in the effectiveness of medications for cough in lung cancer."

Retrospective data • Review • Addiction (Opioid and Alcohol) • Cough • Lung Cancer • Oncology • Respiratory Diseases

PBK_M2301_BE: Evaluation of the Pharmacokinetics of "PBK_M2301" in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Pharmbio Korea Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

PBK_M2301_BE: Evaluation of the Pharmacokinetics of "PBK_M2301" in Healthy Adults (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Pharmbio Korea Co., Ltd.

New P1 trial

Levodropropizine: Comprehensive Review of the Peripheral Antitussive. (PubMed, J Assoc Physicians India) - "Moreover, it has also been extensively studied in diverse age-groups and in multiple etiologies. This comprehensive review aims to summarize the drug aspects, clinical evidence, and place in therapy with levodropropizine."

Journal • Review • Cough • Respiratory Diseases

CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para la TOS (clinicaltrials.gov) - P4 | N=184 | Recruiting | Sponsor: Pontificia Universidad Catolica de Chile | Not yet recruiting ➔ Recruiting

Enrollment open • Cough • Infectious Disease • Respiratory Diseases

Green synchronous spectrofluorimetric analysis of remdesivir, the first approved antiviral, with levodropropizine as add-on therapy for covid-19: application in their pharmaceutical dosage form, and spiked human plasma. (PubMed, BMC Chem) - "The validation of the procedure was successfully completed in compliance with ICH guidelines. In terms of greenness, EcoScale and GAPI greenness tools were used to evaluate the analytical methodology."

Journal • Infectious Disease • Novel Coronavirus Disease

CHAO Tos: Codeina, HederA Helix, LevOdropropizina Para La TOS (clinicaltrials.gov) - P4 | N=184 | Not yet recruiting | Sponsor: Pontificia Universidad Catolica de Chile

New P4 trial • Cough • Infectious Disease • Respiratory Diseases

PREVALENCE AND ASSOCIATED RISK FACTORS OF HEPATITIS B VIRUS INFECTION IN LAFIA METROPOLIS, NASARAWA STATE, NIGERIA. (PubMed, Afr J Infect Dis) - "A cross-sectional study was conducted from September to November 2023, utilizing a validated questionnaire to assess 461 randomly selected participants from four communities (Azuba, Bukan Sidi, Danka Sarki, and Doka), representing diverse sociodemographic profiles and varying degrees of exposure to risk factors associated with HBV infection...These findings highlight the need for targeted public health interventions and policies aimed at reducing HBV transmission among high-risk sociodemographic groups in Lafia Metropolis. This approach could potentially reduce the burden of HBV and improve health outcomes in affected communities."

Journal • Fibrosis • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor

Peripheral antitussives affect temporal features of tracheobronchial coughing in cats. (PubMed, J Appl Physiol (1985)) - "Peripherally acting antitussives 3-Aminopropylphosphinic Acid (3APPi, 5mg/kg) and levodropropizine (Levo, 3mg/kg) were injected i.v. in anesthetized spontaneously breathing cats (13 males, 2 females; 4.38 ± 0.19 kg)...Peripherally induced cough suppression is accompanied with changes in cough temporal characteristics that are not observed after administration of centrally acting antitussives. The motor output produced by the cough central pattern generator differs significantly when coughing is perturbed by peripherally and centrally acting antitussives."

Journal • Anesthesia • Cough • Hypotension • Respiratory Diseases

Management of children with acute post-viral cough: a primary care experience with levodropropizine. (PubMed, Minerva Pediatr (Torino)) - "This experience showed that levodropropizine was an effective and safe remedy for children with acute post-viral cough."

Journal • Cough • Respiratory Diseases

Levodropropizine for children and adolescents with acute post-viral cough: an evidence-based choice. (PubMed, Minerva Pediatr (Torino)) - "Non-pharmacological remedies tend to be safe, but few substances have a documented degree of efficacy. Therefore, when managing children and adolescents with a post-viral cough, the practical approach may be based on levodropropizine use, which is preferable when the cough is particularly persistent and disturbs sleep."

Journal • Cough • Respiratory Diseases • Sleep Disorder

INFURO: The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases (clinicaltrials.gov) - P2/3 | N=102 | Recruiting | Sponsor: University Hospital Hradec Kralove | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Pulmonary Disease • Respiratory Diseases

Green and inventive fluorescence approach for levodropropizine determination in human plasma. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Thorough validation confirmed its reliability, successfully determining LVP in tablets with an average recovery of 98.64 ± 1.07 %. Furthermore, the method's applicability extended to estimate the studied drug in spiked human plasma with excellent obtained percentage recoveries (98.68 ± 1.28-100.14 ± 1.23)."

Journal

Pharmacokinetic Analysis of Levodropropizine and Its Potential Therapeutic Advantages Considering Eosinophil Levels and Clinical Indications. (PubMed, Pharmaceuticals (Basel)) - "Interestingly, changes in an individual's plasma exposure to levodropropizine depending on eosinophil levels could be interpreted as a therapeutic advantage based on pharmacokinetic benefits linked to the clinical indications for levodropropizine. This study presents effective candidate covariates that can explain the inter-individual pharmacokinetic variability of levodropropizine and provides a useful perspective on the first-line choice of levodropropizine in the treatment of inflammatory respiratory diseases."

Journal • PK/PD data • Cough • Hepatology • Respiratory Diseases

INFURO: The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases (clinicaltrials.gov) - P2/3 | N=102 | Not yet recruiting | Sponsor: University Hospital Hradec Kralove

New P2/3 trial • Pulmonary Disease • Respiratory Diseases

Eco-friendly novel deconvoluted synchronous spectrofluorimetric approach for the determination of favipiravir, levodropropizine and moxifloxacin hydrochloride as an effective therapeutic combination for COVID-19; application in laboratory prepared mixtures and spiked human plasma. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "The method's validation was carried out effectively in accordance with guidelines recommended by the ICH. Finally, the Eco-scale and Green Analytical Procedure Index (GAPI) techniques have been used to evaluate the greenness of the proposed method."

Journal • Infectious Disease • Novel Coronavirus Disease

Population pharmacokinetic modeling of levodropropizine: extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "For levodropropizine CR tablets, a high-fat diet significantly delayed gastrointestinal absorption but maintained overall plasma exposure equivalent. This study provides useful quantitative judgment data for precision medicine of levodropropizine and can be helpful in predicting the pharmacokinetics of levodropropizine based on commercialized formulation switching."

Journal • PK/PD data • Chronic Obstructive Pulmonary Disease • Gastrointestinal Disorder • Pulmonary Disease • Respiratory Diseases